Skip to main content

Agilent Technologies, CombiMatrix Molecular Diagnostics

Agilent Technologies this week introduced three new microRNA microarray designs: human miRNA microarray v2.0, mouse miRNA microarray v1.0 and rat miRNA microarray v1.0. All three arrays are based on the version 10.1 of the Wellcome-Trust Sanger Institute’s miRBase, updated in December 2007.
The updated human miRNA microarray v2.0 contains 723 human and 76 human viral probe sets. Viral miRNAs are increasingly associated with some cancers, so the firm said it included these probe sets to provide additional value for cancer researchers.
The new mouse miRNA microarray v1.0 contains all known mouse and mouse gamma herpes virus miRNAs. There are 567 mouse and 10 mouse gamma herpes virus distinct probe sets. The new rat miRNA microarray v1.0 contains all 350 known rat miRNA probe sets, Agilent said.
The Agilent miRNA assays are delivered as eight 15,000-feature arrays per standard 1 inch x 3 inch glass slide. The human v2.0 kit, mouse v1.0 kit and rat v1.0 kit are each available as two different pack sizes: one slide with eight arrays or three slides with 24 arrays. The human, mouse and rat miRNA assays are also available as individual slides, each containing eight microarrays.

CombiMatrix Molecular Diagnostics this week launched its BAC HD Scan test, which is designed to interrogate specific genes and genomic regions associated with over 125 known genetic disorders while enabling screening for unexpected abnormalities.
The test uses CMDX’s bacterial artificial chromosome array technology and includes 2,437 unique validated loci obtained through the company's partnership with the Center of Applied Genomics in Toronto. The array also incorporates the probe content of CMDX’s recently launched ATScan test for Autism Spectrum Disorder, CMDX said.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.